Home / Intelligence / Case Studies / Mapping Payer & Employer Perceptions of Novel Migraine Therapies to Support Access Strategy Development
Trinity conducted a payer and employer advisory board to understand current perceptions of novel migraine therapies and potential strategies to improve access.
Geographic Scope: 
Client Situation
The client wanted to gather the payer and employer perspective on how the migraine landscape is evolving, and pressure test key strategic options as well as messages that they had developed. The employers included: Coca-Cola Company, Metro Nashville Public Schools, St. Louis Community College, and Vibra Healthcare.
Trinity’s Solution
Trinity conducted an unblinded advisory board with a diverse set of payers and employee benefit managers to understand current perceptions of the migraine landscape and the employer interaction with payers as it pertains to influencing employee access to novel migraine therapies.
Deliverables
- Moderator Guide targeting each advisory board stakeholder
- Pre-Survey and Workbook materials designed to capture individual data responses
- Two advisory board sessions where the client played an active role – including individual payer and employer breakout sessions
- Final Report and Executive Summary synthesizing live / written payer and employer insights, highlighting strategic opportunities, challenges, and recommendations
Project Outcomes & Impact
Bringing together both payers and employers into an ad board setting created a real-world dynamic that is not often simulated through market research activities. The feedback within the section on “Cross-Stakeholder Approaches to Engagement on Migraine” provided the client with clear insights on how to effectively engage both stakeholder groups, with a primary output being a tool that payers can use to educate their employer clients on costs associated with migraine and to inform them on how to mitigate costs for their organizations.
Related Intelligence
Webinars
Most-Favored Nation Pricing Policy: Why One Size Doesn’t Fit All
September 25, 2025 | 1:00 – 2:00 PM ET
As U.S. leaders promote a drug pricing vision based on Most-Favored Nation (MFN) principles, ensuring that U.S. consumers have access to the best available prices among advanced nations, pharmaceutical companies are facing increased uncertainty and are evaluating strategic options. This session will bring together Trinity experts to discuss how this initiative could realistically lead to […]
Sign Up Now
Blog
A Shrinking Safety Net: OBBBA’s Ripple Effects on the Pharma Industry
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is the estimated loss of insurance coverage for 16 million people[2], fundamentally reshaping access to care for […]
Read More
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
Available On Demand
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Watch Now